LIFESTYLE

Artiva to Advance NK Cell Therapy Into Phase 3 for Rheumatoid Arthritis After Positive Mid-Stage Data

GC Cell said on May 11 that Artiva Biotherapeutics will advance its NK cell therapy candidate AlloNK (AB-101) into Phase 3 clinical trials for rheumatoid arthritis following positive Phase 2 results.Artiva Biotherapeutics reported meaningful data fro

GF Fermentech Showcases Synthetic Biology CDMO Platform at SynBioBeta 2026

HLB Genex announced on Friday that its subsidiary GF Fermentech recently unveiled its High-Speed Commercialization-Specialized CDMO Platform at the SynBioBeta 2026 conference in San Jose, California.SynBioBeta is the world's leading synthetic biology

Humedix Seeks Domestic Approval for PN-HA Composite Filler Valpien

Huons Group's Humedix is in the final stages of bringing its innovative composite filler Valpien to market, with the goal of securing regulatory approval in the latter half of this year.Humedics announced on Friday that it has submitted an applicatio

JLK Secures Brazil Regulatory Clearance as It Expands AI Imaging Push in Latin America

JLK is set to accelerate its expansion into the Brazilian and Latin American (LATAM) markets with its cutting-edge artificial intelligence (AI)-powered medical imaging analysis solutions.The company announced on Friday that it had secured regulatory

National New Drug Development Project Group Holds 2026 Workshop on Investment Review Strategy

The National New Drug Development Project Group hosted the 2026 Investment Review Committee Workshop at the Westin Chosun Seoul on Friday.This gathering aimed to share global trends in new drug development markets and investment cases, while discussi

FDA Approval Allows AlphaTau to Broaden IMPACT Trial in Pancreatic Cancer

AlphaTau Medical, a Nasdaq-listed company specializing in tumor treatments, is broadening the scope of its multi-center pilot clinical trial (IMPACT) for pancreatic cancer patients in the U.S.The company announced on Thursday that it recently receive

Large-Scale Real-World Study Supports Zacubo’s Efficacy and Safety in GERD Treatment

Onconic Therapeutics recently presented the results of a large-scale Real-World clinical study on their potassium-competitive acid blocker (P-CAB) Zacubo at the 2026 Digestive Disease Week (DDW 2026) in Chicago.The study aimed to validate Zacubo's ef

Novo Nordisk’s Oral Wegovy Just Put Up a Number That Could Change the Obesity Drug Race

Novo Nordisk said first-quarter 2026 sales of its oral obesity treatment known as “oral Wegovy” reached about $400 million in the United States, signaling a strong market debut following its launch in January.During a conference call on May 5 (local

Celltrion’s Zymfentra Just Hit a New U.S. Prescription Record and the Growth Looks Serious

Celltrion said its autoimmune disease treatment Zymfentra, the U.S. brand name for infliximab SC and the world’s only subcutaneous formulation of infliximab, recorded its highest-ever quarterly prescription volume this year.According to Celltrion on

A Long-Acting Oral Drug? Yuhan’s Latest Trial Update Is Turning Heads

Yuhan Corp. said its investigational Gaucher disease treatment candidate YH35995 demonstrated dose-dependent efficacy and long-lasting activity in a Phase 1 clinical trial.The company said Thursday that it presented results from the single ascending